Ariad Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.12.14	Otsuka To Commercialize ARIAD's Iclusig In Japan, Nine Other Asian Countries (RTTNews)
09.12.14	ARIAD Reports Long-Term Safety & Efficacy Data Of Ponatinib From Phase 1 Study (RTTNews)
27.10.14	Ariad Pharma: Will It Return To Its Heyday? (RTTNews)
10.10.14	ARIAD Pharma: PRAC Recommends No Change To Approved Indication For Iclusig (RTTNews)
02.10.14	Ariad's Lung Cancer Gets FDA Breakthrough Therapy Designation (RTTNews)
02.06.14	ARIA Making News, IMMU On The Move, SQNM Does A Deal, Threshold Finds MTD (RTTNews)
31.05.14	ARIAD Reports Data From Discontinued EPIC Trial Of Iclusig - Quick Facts (RTTNews)
31.05.14	ARIAD: Updated Clinical Study Results Show Anti-tumor Activity Of AP26113 (RTTNews)
25.03.14	AMRI Opens Wallet, IDIX To Fight Back, QRxPharma Awaits FDA Panel Verdict (RTTNews)
24.03.14	Ariad Initiates Pivotal Phase 2 ALTA Trial Of AP26113 In Patients With NSCLC (RTTNews)
25.02.14	ARIAD Pharma Q4 Loss Widens - Quick Facts (RTTNews)
17.01.14	Pre-market Movers For Jan 17 (GE, INTC, MS, UPS, ARIA, NIHD, RDEN, AAWW) (RTTNews)
23.12.13	ARIA On Resurrection, XON Opens Wallet, NUVA In Work Mode, ORMP's Sweet Tidings (RTTNews)
22.11.13	Pre-market Movers For Nov 22 (ARIA, ARUN, BIIB, POZN, FL, SPLK, ROST) (RTTNews)
22.11.13	Ariad Announces Positive CHMP Opinion On Continued Availability Of Iclusig (RTTNews)
12.11.13	Ariad Pharma Q3 Loss Widens Amid Increased Expenses, Revenue Surges (RTTNews)
08.11.13	Ariad Pharma To Cut 40% Of Workforce In U.S. - Quick Facts (RTTNews)
31.10.13	Pre-market Movers For Oct 31 (FB, XOM, CAH, OPTT, EXPE, NIHD, ARIA) (RTTNews)
19.10.13	Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Ariad Pharmaceuticals Inc. (PR Newswire)
18.10.13	Ariad Halts Iclusig Trial; Shares Plunge Over 38% (RTTNews)
18.10.13	Pre-market Movers For Oct 18 (GE, GOOG, FB, ANAC, SLB, ARIA, PSDV, ALIM, HON) (RTTNews)
18.10.13	Ariad Stops Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed CML (RTTNews)
14.10.13	Trial Updates and Public Offering - Research Report on Gilead, Celgene, Ariad, Puma Biotechnology, and Dyax (PR Newswire)
13.10.13	Lifshitz Law Firm Announces Investigation of Achillion Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc., Brazil Fast Food Corp. and Camco Financial Corporation (PR Newswire)
10.10.13	Pre-Market Review: MannKind Corp., Galena Biopharma Inc., Ariad Pharmaceuticals Inc., and Novavax Inc. (PR Newswire)
10.10.13	Morgan & Morgan Announces the Investigation of Ariad Pharmaceuticals ARIA (PR Newswire)
10.10.13	ARIA Loses Pace, DVAX On The Move, BDSI, CHTP Get FDA Dates, ACUR Buys Peace (RTTNews)
09.10.13	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ariad Pharmaceuticals, Inc. - ARIA (PR Newswire)
09.10.13	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ariad Pharmaceuticals, Inc. (PR Newswire)
09.10.13	Pre-market Movers For Oct 9 (AA, MW, JOSB, FDO, ARIA, LXRX, ICPT, FAST) (RTTNews)
09.10.13	ARIAD Pharma Reveals Changes In Clinical Development Program Of Iclusig (RTTNews)
16.09.13	Alexandria Real Estate Equities, Inc. Executes Lease Amendment with ARIAD Pharmaceuticals, Inc. for Remaining 142,000 RSF at 75/125 Binney Street Build-to-Suit Facility in Cambridge, Massachusetts (PR Newswire)
10.09.13	Technical Scrutiny: Novavax Inc., MannKind Corp., Galena Biopharma Inc., and Ariad Pharma Inc. (PR Newswire)
09.09.13	Appointments, Successful Clinical Trials, Mergers, and New Contracts Boost Growth - Research Report on BioMarin, ARIAD, Bard, Rockwell Medical, and Health Net (PR Newswire)
05.09.13	THRX Breathes Easy, POZN Pops, RNN Begins Anew, ARIA On The Move (RTTNews)
04.09.13	ARIAD Reaches 50% Patient Enrollment In Late-stage EPIC Trial Of Iclusig (RTTNews)
12.08.13	New Care Organizations, Board Appointments, and Strong Top Line Growth Reports - Research Report on UnitedHealth, WellPoint, WellCare, ARIAD, and DexCom (PR Newswire)
02.08.13	Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax (PR Newswire)
04.01.10	ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference (Businesswire)
07.12.09	ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting (Businesswire)
23.11.09	ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting (Businesswire)
14.09.09	ARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas (Businesswire)
06.01.09	ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology (Businesswire)
09.12.08	ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl (Businesswire)
24.10.08	ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors (Businesswire)
07.10.08	Ariad Appoints Two New Members to Its Board of Directors (Businesswire)
07.11.07	ARIAD Reports Third Quarter 2007 Results (Businesswire)
12.07.07	ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer (Businesswire)
09.05.05	ARIAD To Webcast Conference Call On AP23573 Clinical Results Presented (Businesswire)
02.05.05	ARIAD Files IND to Initiate Clinical Trials of Oral Dosage Form of AP2 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	209.50	2.80 %	K V
CieFinRichemont	179.00	1.76 %	K V
Novartis	98.04	1.13 %	K V
Nestle	78.20	1.09 %	K V
ABB	50.60	1.04 %	K V
Part Grp Hldg	1’409.00	0.18 %	K V
Givaudan	3’829.00	0.03 %	K V
UBS Group	30.30	-0.03 %	K V
Swiss Re	141.70	-0.21 %	K V
Roche Hldg G	288.20	-0.83 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ariad Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten